Differentiation of mesenchymal stem cells from human amniotic fluid to cardiomyocyte-like cells

23Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Ischemic heart disease (IHD) is a major factor influencing worldwide mortality rates. Furthermore, IHD has become a significant health problem among the Thai population. Stem cell therapy using mesenchymal stem cells (MSCs) is an alternative therapeutic method that has been applied to improve the quality of life of patients. Amniotic fluid (AF) contains a heterogeneous cell population, including MSCs, which are multipotent stem cells that have the capability to differentiate into mesenchymal lineages. The purpose of the present study was to evaluate the MSC characteristics of human (h)AF and determine its potency regarding cardiogenic differentiation. MSC characterization following flow cytometric analysis revealed that the cells expressed MSC markers, cluster of differentiation (CD)44, CD90, human leukocyte antigen-ABC and CD73. The results of the alamar blue assay demonstrated that cell proliferation rate continuously increased from the early cultivation phase up to 5-fold during days 1 to 5 of cell culturing. The highest rate of cell proliferation was observed on day 17 with a 30-fold increase compared with that on day 1. During the cardiogenic induction stage, morphological changes were observed between day 0 and day 21, and it was revealed that the hAF derived-MSCs in the cardiogenic-induced group exhibited myotube-like morphology after 7 days of cell culturing. Following cardiogenic induction, immunohistochemistry staining was performed on day 21, and reverse transcription-quantitative polymerase chain reaction on day 7 and 21. These steps were performed to detect the protein and gene expression levels of cardiac specific proteins (GATA4, cardiac troponin T, Nkx2.5 and Connexin43). The results of the present study indicated that hAF-MSCs possess the potential to differentiate into cardiomyocyte-like cells. Thus, it was concluded that hAF may be a suitable source of MSCs for stem cell therapy and tissue engineering.

References Powered by Scopus

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

14645Citations
N/AReaders
Get full text

Cardiomyocytes can be generated from marrow stromal cells in vitro

1752Citations
N/AReaders
Get full text

Isolation of amniotic stem cell lines with potential for therapy

1644Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Adult Stem Cells for Bone Regeneration and Repair

187Citations
N/AReaders
Get full text

Cardiac remodeling and repair: Recent approaches, advancements, and future perspective

20Citations
N/AReaders
Get full text

Combination of human amniotic fluid derived-mesenchymal stem cells and nano-hydroxyapatite scaffold enhances bone regeneration

18Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Markmee, R., Aungsuchawan, S., Narakornsak, S., Tancharoen, W., Bumrungkit, K., Pangchaidee, N., … Puaninta, C. (2017). Differentiation of mesenchymal stem cells from human amniotic fluid to cardiomyocyte-like cells. Molecular Medicine Reports, 16(5), 6068–6076. https://doi.org/10.3892/mmr.2017.7333

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

65%

Researcher 3

18%

Lecturer / Post doc 2

12%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 7

44%

Medicine and Dentistry 4

25%

Agricultural and Biological Sciences 3

19%

Pharmacology, Toxicology and Pharmaceut... 2

13%

Save time finding and organizing research with Mendeley

Sign up for free
0